Vemlidy’s active competition in chronic hepatitis B treatment market

Published: 2017-11-14 16:30:00
Updated: 2017-11-14 16:50:45

Gilead Sciences’ ‘Vemlidy Tab’ has entered general hospitals one after another, which raises an expectation on its sales performance in the future.

‘Vemlidy,’ a Gilead Sciences’ chronic hepatitis B treatment whose health insurance benefit has started to be applied on both first and resistance pa...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.